ArticleMedical microbiology and immunology2011
Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.
Article in Medical microbiology and immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Hepatitis B vaccination coverage in Germany: systematic review.BMC infectious diseases · 2021Pooled it
- Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.AIDS (London, England) · 2016Pooled it
- Antiretroviral Therapy Within 2 Years of HIV Acquisition Is Associated With Fewer Viral Blips: A Retrospective Analysis of More Than 20 Years of Data From the US Military HIV Natural History Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.Frontiers in public health · 2020Article
- Article
- Article
- Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.Medical microbiology and immunology · 2017Article
- Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.Croatian medical journal · 2016Article
- Hepatitis E virus infection in the liver transplant recipients: Clinical presentation and management.World journal of hepatology · 2016Review
- Factors associated with HIV RNA viral loads in ART-naïve patients: implications for treatment as prevention in concentrated epidemics.Journal of virus eradication · 2016Article
- Viral hepatitis and human immunodeficiency virus co-infections in Asia.World journal of virology · 2015Review
- Hepatitis B virus infection in a cohort of HIV infected blood donors and AIDS patients in Sichuan, China.Journal of translational medicine · 2014Article
- Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: a point prevalence study.HIV medicine · 2014Article
- Hepatitis B and C co-infection in HIV/AIDS population in the state of Michigan.Epidemiology and infection · 2013Article
- Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia.Medical microbiology and immunology · 2013Article
- Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.Medical microbiology and immunology · 2012Article
- Recent publications in medical microbiology and immunology: a retrospective.Medical microbiology and immunology · 2012Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In HIV-infected treatment-naïve patients, we analyzed risk factors for either chronic hepatitis B (HBV) infection, occult HBV infection (OHBV) or a positive hepatitis C (HCV) serostatus. A total of 918 patients of the RESINA-cohort in Germany were included in this study. Before initiating antiretroviral therapy, clinical parameters were collected and blood samples were analyzed for antibodies against HIV, HBV and HCV, HBs antigen and viral nucleic acids for HIV and HBV. Present or past HBV infection (i.e. HBsAg and/or anti-HBc) was found in 43.4% of patients. HBsAg was detected in 4.5% (41/918) and HBV DNA in 6.1% (34/554), resulting in OHBV infection in 2.9% (16/554) of patients. OHBV infection could not be ruled out by the presence of anti-HBs (50.1%) or the absence of all HBV seromarkers (25%). A HCV-positive serostatus was associated with the IVDU transmission route, non-African ethnicity, elevated liver parameters (ASL or GGT) and low HIV viral load. Replicative HBV infection and HCV-positive serostatus both correlated with HIV resistance mutations (P = 0.001 and P = 0.028). HBV and HCV infection are frequent co-infections in HIV treatment-naive patients. These co-infections influence viral evolution, clinical parameters and serological markers. Consequently, HIV patients should routinely be tested for HBV and HCV infection before initiating HIV treatment. OHBV infection constituted almost half of all HBV infections with detectable HBV DNA. Due to a lack of risk factors indicating OHBV infection, HBV diagnosis should not only include serological markers but also the detection of HBV DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.